Just another guy with a day job and an obsession with the stock market... my goal is to achieve FI (financial independence) by investing in growth and turnaround stocks.
Value Catalyst Investor/Value Where I can Find It
I strive to provide actionable ideas that are capable of generating alpha for my readers, while never losing my sense of skepticism in the midst of the chaotic mix of euphoria and pessimism known as Wall Street.
Remember, there are no shortcuts. Do your own research, get your financial house in order, have your own sell rules, and check your ego at the door, as the market eventually humbles us all time and again.
2016 Favorite Winners Identified for Readers (Start Date June 12):
Galapagos (GLPG)- Identified as core biotech holding whose assets were largely undervalued by the market, with upcoming catalysts in cystic fibrosis & IPF, not to mention heavy weight partnerships and being a possible medium term acquisition target
Apigee (APIC) identified as key IoT play for readers, bought out by Google
Retrophin (RTRX) identified as core biotech holding trading at a depressed valuation due to involvement with prior CEO, where commercial business worth more than present valuation and pipeline offered near term upside potential
Zynerba Pharmaceuticals (ZYNE)- Identified relative value disconnect between early stage marijuana biotech and late stage competitor GWPH, arguing that near term catalysts could shorten gap from 30x to 4-8x
*A final note, I´m very thankful to Seeking Alpha for creating a transparent forum where investors can share their ideas, DD, strategies and high conviction picks. I appreciate every follow and the positive feedback I´ve been getting- it´s why I keep at it. Constructive criticism, bear thesis on my long picks, and other ideas on how to improve articles for readers are always welcome (when done in a civil manner).
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (in partnership with Seeking Alpha).
Licensed Investment professional. Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon. Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com.
Registered Investment Advisor in Massachusetts. The firm also operates a private pooled investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Ever feel like trading is like rolling dice? In a way, it is, because every mathematical model of the market includes a stochastic aspect. But I believe we can load the dice in our favor through the use of statistics. Understanding both the stock market and each individual stock as a sort of random process with its own characteristics allows us to more accurately predict what it will do in the future. Coupling statistics with fundamental analysis, I have the goal of revealing to you the hidden patterns within stocks so that you may do what you wish with that information.
My name is Tarun Chandra, and I've been an Analyst on both the Buyside and Sellside. In addition, I've worked in a Corporate Strategy and Finance role for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for individual investors. Prudent Biotech portfolio is a quantitative-driven systematic investing product. More can be learnt about our Biotechnology portfolio, including Performance and Samples, at the website Prudent Biotech. You may also visit our main website Graycell Advisors for a view of our Investment Approach and all Newsletters with samples.
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
The resource referenced below can be deceptively inaccurate, though it is the only known site that tracks the performance of stocks written about through Seeking Alpha (when using the S&P 500 as a benchmark):
Important information follows, please click the link below to review it all:
Work presented may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but instead represent only the author's belief regarding future events, many of which, by their nature, are inherently uncertain and outside his control. Except for the author's obligation to disclose material information, the author is not under any obligation (and expressly disclaims any obligation) to update or alter any projections, goals, assumptions, or other statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
No content within the author's work is a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person or purpose. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content of this article may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to specific investment needs. The author is not an investment advisor and is not offering investment advice. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published will not contain a list or description of relevant risk factors. Some of the stocks about which the author has written and writes about have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Any information in the author's work deemed by you to be recommendations may have an effect on their stock prices.
The author's publications are not intended to provide tax, legal, insurance or investment advice, and nothing presented in the author's work should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Seeking Alpha or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.
All information in this report is provided "as is" without warranty, expressed or implied, or representations of any kind to the fullest extent permissible under applicable law, the author will not be liable for the quality, accuracy, completeness, reliability, or timeliness of this information, or for any direct, consequential, incidental, special or punitive damages that may arise out of use of this information by you or anyone else, including but not limited to lost profits, loss of opportunities, trading losses, and damage that may result from any inaccuracy or incompleteness of this information to the fullest extent permitted by law. The author denies liability to you or anyone else under any tort, contract, negligence, strict liability, products liability, or other theory with respect to presentation of information.
The information, opinions, data, quantitative and qualitative statements communicated have been obtained from sources believed to be reliable but have not been independently verified and are not guaranteed as to accuracy nor does it purport to be a complete analysis of every material fact regarding the company, industry, or security. The information, opinions, or recommendations are solely for informational purposes and are only valid as of the date appearing on the report and are subject to change without notice. You recognize that performance data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that such calculations are not guaranteed by these sources, the information providers, or any other person or entity, and may not be complete.
The author writes about and invests in high risk companies, some of which succeed, and some of which go out of business completely, rendering securities, including bonds, preferred stock, common stock, options and other financial derivatives valueless.
The author does not intend to receive any inside information from any of the companies written about.
Investors are encouraged to read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Prescient Investment Analysis is a person. BA, Boston College, Philosophy.
ARK Invest holds a precision lens on thematic investing. We focus on disruptive innovation and identify themes that will enhance productivity and create wealth. ARK seeks to research and invest in technologically enabled innovation that cuts across economic sectors and changes the way our world works. Our current themes include: Industrial Innovation, Web x.0, and the Genomic Revolution.
Innovation is inevitable, and ultimately wins out in an equity market. ARK manages an in-house research team allowing identification of secular shifts prior to their market reflection. ARK's unique research ecosystem leverages multiple data streams, both internal and external, that result in original analysis. Our research is made available on our website and we invite everyone to participate in our discussions around thematic investing in innovation. For more information please visit: http://ark-invest.com
Michael Kramer is the founder and PM of MCM.
Michael Kramer is a thematic growth investor. He likes to think about themes in society and find long term equity investments that fit those themes.
Michael is the founding member of Mott Capital Management, LLC in 2014. Prior to MCM Michael spent the previous 10 years working as a domestic and international equity trader. During this time he was responsible for handling trades in some of the most illiquid equities. Additionally, Michael has experience trading in some of the most exotic foreign markets.
Mott Capital Management is a Thematic Growth investor using themes and trends in life to find exciting growth stories. Once we find a theme we want to capitalize on we begin searching for products that interact with the end user. From there we begin the company search process. We are long-term because that is our edge. We understand and recognize when events are critical and when they are not. We also believe it is a way to neutralize market volatility.
Suhail Capital Management is a Cayman Domiciled Private Investment Firm. We focus on event driven long/short opportunities in what we believe to be seriously mispriced global listed securities.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) email@example.com.
After a trial period writing for SA, it appears that the editorial policies favour short-term view articles with little relevance with the valuation of the company. To maximise my gains, I would have to write shorter non relevant articles. I am not going to do that, so I guess this is goodbye.
Well, that was fun while it lasted !
At Young Money Monsters we believe in teaching both young and experienced investors the analysis process while offering our own evaluations of securities. It is our mission to create a more intelligent and confident world of personal finance and encourage investment in the United States financial markets. We will release content through a variety of mediums to illuminate the analysis process. Through sharing our own findings we will depict the analysis process to beginning investors while remaining as a source of knowledge for all. Our intention behind the formation of Young Money Monsters was to provide a new platform for all investors to engage in conversation and experience the debates that often occur when discussing investing in any individual company; for this reason, we encourage our readers to send us any questions or points of conversations they would like to see addressed on our site. We are excited to interact with each of our readers and believe that this unique focus on conversation positions us to create one of the internet’s most engaged audiences. The reader experience is truly at the heart of everything we do.
Tim spent 10 years in the private wealth management business with several firms including Merrill Lynch, Bank of America and Wachovia Securities. Tim had assets totaling over $50 million under management at the time of his retirement. He continues to advise several private accounts as well as his own.
For an accurate look at my article performance, please click on the following link:
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.
An experienced research and advisory team of Traders and Forecasters have combined to offer free services and alerts at StockReversals.com, A free growth stock profile, research and alert service with benefits. Go to the website to subscribe for free. We also offer StockReversalsPremium.com which offers a combination of long term growth stock profiles with massive upside potential, plus swing position trading (days to 8 weeks holding).
Seeking Alpha Certified and Frequent Contributor to numerous financial websites. We specialize in behavioral analysis as it applies to market patterns and reversal trends. These trends happen over short term, intermediate, and long term time frames. We help our free subscribers with Business Disruptor growth stocks that crush the market. Sample picks include FB, YY, DATA, INVN, SPCB, MOBI, CUR and many more. In 6 months we had 6 doubles, 1 triple, and 16 of 19 companies up 30-50% or more.
Our work centers around a combination of Elliott Wave Theory, Technical Analysis, Human Behaviors, Sentiment, and Business Disruption analysis.
We have advisory clients from around the world. South Korea, Australia, Canada, Sweden, Germany, The Netherlands and of course the U.S.
We give away our service for free because of the laws of nature which we have on our website:
“The possession of knowledge, unless accompanied by the manifestation and expression in sharing is a vain and foolish thing. The Law of Use is universal, and he who violates it suffers by reason of his conflict with natural forces.”
Join us today at stockreversals.com and sign up for free.
I participate in Angel Investing and Venture Capital transactions. I have four years of experience in the Capital Markets. This includes, as a Qualified Investor, Angel Investing, Private Equity, Portfolio Management and Equity Trading. I achieved a Bachelors Degree in Business Finance at the University of Northern Colorado.
My preferred method of contact is via email at: firstname.lastname@example.org
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
I worked almost 30 years in the pharmaceutical industry. I started as a sales rep after earning my degree in biological sciences and (later) biomedical sciences. I then went back to school, got my MBA, and spent the following 20 years working up the ranks. I spent the latter parts of my career working as an analyst, meaning I would analyze data on 1,000s of compounds, collect reports from scientists, and then present the information to those who decided whether the candidates would go on to clinical trials (additional preclinical studies) or would be thrown to the dumpster for some small company to find and develop further. I have worked in just about every department in the pharmaceutical industry, including biotechnology, oncology, infectious disease, genetics, etc.
Now that I am recently retired, I have joined Seeking Alpha to share my knowledge of the healthcare industry, and discuss trends that I've seen throughout my career. I have chosen the task of managing my own retirement accounts, therefore Seeking Alpha has become a great interest to me.
I am hoping to learn and teach via Seeking Alpha. Also, my grandchildren call me Shennie so that's what I go by these days
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.